CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 104 enrolled
Drug / intervention
bimatoprost ophthalmic solution 0.005% +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01064882
NCT01064882Phase 2Completed
CompareCT.gov

Safety and Efficacy of Bimatoprost Ophthalmic Solution in Increasing Eyelash Prominence

Allergan·interventional·Posted Feb 9, 2010·Updated Dec 9, 2011

In Brief

A Phase 2 clinical trial evaluating bimatoprost ophthalmic solution 0.005%, bimatoprost ophthalmic solution 0.015%, and 1 other intervention for Eyelash Hypotrichosis. Completed, enrolled 104 participants across 1 site.

Detailed Summary

This study will evaluate the safety and efficacy of bimatoprost ophthalmic solution 0.005% or 0.015% compared with bimatoprost ophthalmic solution 0.03% once-daily application to the upper eyelid margins in increasing eyelash prominence

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEyelash Hypotrichosis
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedFeb 9, 2010
Enrollment StartMar 1, 2010
Primary CompletionJul 1, 2010
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 16.4 years ago

Interventions

bimatoprost ophthalmic solution 0.005%drug

One drop applied to a sterile single-use-per-eye applicator and applied to upper eyelid margins (where the eyelashes meet the skin)

bimatoprost ophthalmic solution 0.015%drug

One drop applied to a sterile single-use-per-eye applicator and applied to upper eyelid margins (where the eyelashes meet the skin)

bimatoprost ophthalmic solution 0.03%drug

One drop applied to a sterile single-use-per-eye applicator and applied to upper eyelid margins (where the eyelashes meet the skin)